Department of Obstetrics and Gynecology, Division of Family Planning, and the Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Obstet Gynecol. 2019 Oct;134(4):807-813. doi: 10.1097/AOG.0000000000003452.
To estimate whether serum etonogestrel concentrations influence bleeding patterns and related side effects in contraceptive implant users.
We conducted a prospective cross-sectional study with healthy, reproductive-aged women using etonogestrel implants for 12-36 months. Participants completed a brief questionnaire to assess their current bleeding pattern and any experience of abnormal bleeding with the implant. We then measured serum etonogestrel concentrations. We also reviewed the charts of participants to determine whether a prescription for oral contraceptive pills was ever given for treatment of implant-related bothersome bleeding. We performed multivariable logistic regression to test for associations between serum etonogestrel concentrations and both bleeding patterns and related side effects.
We enrolled 350 women, and 59.4% reported having experienced abnormal bleeding with the contraceptive implant. Only 14.9% of participants reported amenorrhea and 37.7% reported monthly periods. Among participants with reviewable medical records (n=253), roughly 20% had received a prescription for oral contraceptive pills during implant use. Increasing serum etonogestrel concentrations were significantly associated with increasing odds of reporting abnormal bleeding (adjusted odds ratio [aOR] 1.005, P=.015) and increasing odds of having received an oral contraceptive pill prescription (aOR 1.008, P=.002). For every 100 pg/mL increase in serum etonogestrel concentration, contraceptive implant users in this study had 1.6 times the odds of reporting abnormal bleeding and 2.3 times the odds of having received a prescription as treatment for bothersome bleeding.
We found both objective and subjective evidence that higher levels of progestin from the contraceptive implant were associated with bleeding side effects experienced by women in this study. Pharmacologic variation may influence the side effects women experience with a variety of hormonal contraceptive methods, in turn affecting patient satisfaction and discontinuation rates.
评估避孕药中依托孕烯的血清浓度是否会影响避孕植入物使用者的出血模式和相关副作用。
我们进行了一项前瞻性的横断面研究,纳入了使用依托孕烯避孕植入物 12-36 个月的健康、育龄期女性。参与者完成了一份简短的问卷,以评估其当前的出血模式和任何与植入物相关的异常出血经历。然后,我们测量了血清依托孕烯浓度。我们还查阅了参与者的图表,以确定是否曾因与植入物相关的恼人出血而开具口服避孕药处方。我们进行了多变量逻辑回归分析,以检验血清依托孕烯浓度与出血模式和相关副作用之间的关系。
我们共纳入了 350 名女性,其中 59.4%报告使用避孕植入物后出现异常出血。仅有 14.9%的参与者报告闭经,37.7%报告每月出血。在可查阅病历的参与者中(n=253),约 20%在使用植入物期间接受了口服避孕药的处方。血清依托孕烯浓度升高与报告异常出血的几率增加显著相关(调整后的优势比[aOR]1.005,P=.015),与接受口服避孕药处方的几率增加也显著相关(aOR 1.008,P=.002)。在这项研究中,血清依托孕烯浓度每增加 100 pg/mL,避孕植入物使用者报告异常出血的几率增加 1.6 倍,接受避孕药处方治疗出血问题的几率增加 2.3 倍。
我们既有客观证据也有主观证据表明,避孕药中孕激素水平升高与本研究中女性经历的出血副作用有关。药物代谢的差异可能会影响女性使用各种激素避孕方法时的副作用体验,进而影响患者的满意度和停药率。